Increased cancer risk after myocardial infarction: fact or fiction? A systemic review and meta-analysis
Authors Li N, Huang Z, Zhang Y, Sun H, Wang J, Zhao J
Received 6 November 2018
Accepted for publication 27 January 2019
Published 1 March 2019 Volume 2019:11 Pages 1959—1968
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Na Li,1,* Zhigang Huang,1,* Yanda Zhang,1,* Haitao Sun,2 Jiamei Wang,1 Jian Zhao1
1Department of Cardiology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China; 2Department of Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
*These authors contributed equally to this work
Objective: Accumulating evidences showed some positive relations between myocardial infarction (MI) and new onset cancer. We aim to investigate whether MI is associated with an increased risk of incident cancer.
Methods: A comprehensive literature list was identified from MEDLINE, Embase, and Web of Science databases from inception until October 2018. The main inclusion criteria included observational studies investigating the association between MI and new onset cancer. Stata 12.0 software was used for meta-analysis.
Results: Of 862 potentially relevant studies, five cohort studies met all inclusion criteria. The pooled cancer incidence rate was 9.5% (95% CI=8.3–10.7%). Pooled analysis of OR showed that the increased overall cancer risk in MI patients in comparison with controls had no statistical significance (OR=1.08; 95% CI=0.97–1.19, P=0.153). Subgroup analysis by gender demonstrated that the overall cancer risk was only significantly increased in female (OR=1.10; 95% CI=1.01–1.20, P=0.025), but not in male patients (OR=1.04; 95% CI=0.99–1.10, P=0.124). In terms of cancer type, the increased cancer risk was only significant for lung cancer (male OR=1.12; 95% CI=1.05–1.19, P<0.01; and female OR=1.51; 95% CI=1.15–1.99, P<0.01), but not for prostate (OR=0.96; 95% CI=0.85–1.09, P=0.546) or breast cancer (OR=0.94; 95% CI=0.86–1.04, P=0.222). In addition, the increased cancer risk was only significant in the first 6 months (OR=1.93; 95% CI=1.42–2.63, P<0.01) but not in 6 months–1-year (OR=1.03; 95% CI=0.92–1.15, P=0.627) or >1-year (OR=0.98; 95% CI=0.93–1.04, P=0.585) follow-up after MI.
Conclusion: From available evidence, the increased overall cancer risk after MI was only significant in female but not in male patients. Besides, the increased cancer risk could be driven by increased short-term cancer incidence after MI and certain cancer types such as lung cancer.
Keywords: myocardial infarction, incident cancer, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]